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Background: In chronic heart failure (CHF) patients there is a wide variability in the minimal effective diuretic
dose. The aim of this study is to evaluate whether renal resistance index (RRI) is associated to baseline diuretic
dose and the changes at one year.
Methods and results: 250outpatients in a stable condition and in conventional therapywere enrolled. Baseline RRI
was calculated by renal arterial Doppler. The total daily dose of loop diuretics was assessed at baseline and after
one year. High diuretic dose (HDD) was deﬁned as a daily furosemide equivalent dose N100 mg. RRI
was independently associated with baseline HDD at univariate (OR 1.39; 95% CI: 1.233–1.58; p b 0.001) and
multivariate analysis (OR 1.27; 95% CI: 1.09–1.49; p: 0.002) after correction for other univariate predictors
(age, NYHA class, left ventricular ejection fraction, tricuspid annulus peak of systolic excursion, NT-proBNP,
glomerularﬁltration rate by EPI formula and central venous pressure).Moreover, baseline RRIwas independently
associated to one year stable increase in loop diuretic dose at univariate and multivariate regression analyses.
Conclusions: RRI is independently associated with high dose loop diuretics and their increase during a mid-term
follow-up thus suggesting its usefulness in detecting an altered diuretic response in CHF outpatients.© 2015 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In chronic heart failure (CHF) patients diuretic therapy plays a key
role in the relief of symptoms due to ﬂuid overload aswell as the control
of both intracardiac and intravascular ﬁlling pressure [1]. However,
diuretics are also affected by possible negative effects [2,3] and
consequently, theminimumdosage necessary to keep patients in stable
clinical conditions is generally prescribed [1]. It is worth noting that this
dosage can vary greatly among patients due to the variability of dose–
response curves. When a diuretic dose–response curve shifts down-
wards and to the right in CHF, a higher dose of diuretics is necessary
in order to achieve the same level of sodium excretion [3].
The alterations of dose–response curves in CHF are related to several
renal factors responsible for a reduced nephron response, such as a
reduction in glomerular ﬁltration rate, distal convoluted tubule cell
hypertrophy, and the activation of adrenergic and renin–angiotensin–
aldosterone systems [4]. Moreover, all these mechanisms can cause
abnormalities in renal perfusion which can further contribute to aent of Emergency and Organ
11, 70124 Bari, Italy. Tel.: +39
. Iacoviello).
is an open access article under the Creduced diuretic response and to the progressive evolution towards
diuretic resistance [5]. In this setting, the estimation of renal perfusion
and renal arterial resistances could help the clinician to better charac-
terise the pathophysiological background and the need for higher dose
diuretics.
Renal arterial resistance index (RRI), a parameter reﬂecting vascular
[6] and parenchymal renal abnormalities [7], has recently been pro-
posed as a useful tool in detecting renal perfusion abnormalities and
identifying patients prone to heart failure progression [8]. The aim
of this study was to evaluate whether RRI is also independently associ-
ated to diuretic dose and to its mid-term increase in a group of CHF
outpatients.2. Methods
Outpatients with CHF of any origin who had been referred to the
Heart Failure Unit of the University of Bari between January 2010 and
January 2013 were enrolled in the study. At enrolment, those who had
been clinically stable for at least 30 days and had been on conventional
medical and electrical therapy for at least 3 months were included. Pa-
tientswith acute decompensated heart failure (ADHF), acuteworsening
of kidney function or renal failure requiring dialysis or transplantationC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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from all patients.
This was a secondary analysis of a study that had been approved by
the local ethics committee, the main ﬁndings of which have already
been published [8].
2.1. Baseline evaluations
At enrolment, a medical visit, an ECG, an echocardiographic exami-
nation and a renal arterial Doppler evaluation were performed.
2.2. Medical examination and electrocardiogram
A documented record of the patients' ischemic heart disease, arterial
hypertension and diabetes mellitus was made. Cardiovascular drugs
taken by patients were accurately documented. The New York Heart
Association (NYHA) class, weight, height, systolic and diastolic arterial
pressure were also evaluated and a 12-lead ECG was performed to
evaluate heart rhythm and heart rate.
2.3. Echocardiographic evaluation
Echocardiographic images were obtained using an echocardiograph
(Vivid 7, GE Vingmed Ultrasound, General Electric, Milwaukee, WI)
equipped with a 4 MHz probe. Left ventricular end-diastolic and end-
systolic volume and left ventricular ejection fraction (LVEF) were calcu-
lated using Simpson's rule [9]. Right ventricular systolic function was
assessed by measuring the systolic peak of tricuspid annular plane
excursion (TAPSE).
Colour Doppler semi-quantitative evaluation of mitral regurgitation
(MR) and tricuspid regurgitation (TR) was performed, with arbitrary
units ranging from 0 to 4. Dilatation of the inferior vena cava and its col-
lapsibility during inspirationwere evaluated in order to estimate central
venous pressure (CVP). In presence of a vena cava of normal diameter
with good collapse CVP was estimated at 3 mm Hg, a dilated vena
cava with poor collapse was estimated at 15 mm Hg, in intermediate
cases the estimate was 8 mmHg [10]. Pulmonary arterial systolic pres-
sure (PASP) was evaluated by calculating the peak velocity of tricuspid
regurgitation and estimated CVP [10].
2.4. Chemical evaluations
Blood samples were taken to evaluate amino-terminal brain natri-
uretic peptide NT-proBNP (immunoassay Dade Behring, Eschborn,
Germany) and serum creatinine (mg/dl). The glomerular ﬁltration rate
was calculated using the abbreviated CKD-EPI formula (GFR-EPI,
ml/min/1.73 m2) [11].
2.5. Renal arterial echo-colour Doppler
Renal arterial Doppler was performed after echocardiographic ex-
amination with the same echograph (Vivid 7, GE Vingmed Ultrasound,
General Electric,Milwaukee,WI) and the same 4MHzprobe, bymoving
the patient to the sitting position and using a posterior approach to
the kidney. The course of right or left renal segmental arteries was
visualised by colour Doppler ﬂow and pulsed Doppler was performed
at the mid-tract level of the best one visualised. Every effort was made
to obtain the best alignment of the ultrasonic beam. An average of 2 to
3 measurements of peak systolic velocity and end-diastolic velocity
was used to calculate the renal arterial resistance index according to
Peurcelot's formula, i.e. 100 × [1− (end diastolic velocity / peak systolic
velocity)] [12]. Patients with a Doppler pattern suggesting renal artery
stenosis [13,14] were excluded. A single operator, blinded to baseline
diuretic dose, measured RRI.2.6. Diuretic therapy and follow-up
The clinical practice in our Heart Failure Unit is to progressively re-
duce diuretic dose, if possible, based on the clinical conditions and
changes in echocardiographic examinations. The minimum diuretic
dose which can maintain patients in a stable clinical condition is gener-
ally prescribed. Patients are followed-up with scheduled visits (every
one to six months according to NYHA functional class impairment) or
with unscheduled visits in cases ofworsening clinical status. The diuret-
ic dose is increased in the case of worsening of symptoms or signs of
congestion or after acute decompensated heart failure admission.
At the time of enrolment, all patients had been taking theminimum
dose of diuretics for at least 30 days. The daily furosemide equivalent
dose was calculated for each patient taking loop diuretics. High
diuretic dose (HDD) has been deﬁned as an equivalent furosemide
dose N 100mg/die, that is 4 times theminimal basal dose [15]. The furo-
semide equivalent dose was reassessed after 1 year. The stable increase
of ≥50% in the equivalent furosemide basal dose at 1 year follow-up
was considered as the end-point reﬂecting a signiﬁcant increase in
diuretic dose.
2.7. Statistical analysis
Continuous variables are expressed as mean ± standard deviation.
Categorical variables are reported as frequencies and percentages.
The between-group comparisons were made by analysis of variance
(ANOVA) followed by theNewman–Keuls test formultiple comparisons
for continuous variables. For categorical variables chi-squared and
McNemar tests were used as appropriate. The receiving operating char-
acteristic (ROC) curves for sensitivity and speciﬁcity were constructed
in order to evaluate the diagnostic accuracy of RRI in predicting diuretic
increase by the areas under the curves (AUC). The best cut-off for the
end-point analysed was deﬁned on the basis of the greatest sum of
sensitivity and speciﬁcity.
A multivariate logistic regression analysis was performed in order
to deﬁne the parameters independently correlated to HDD and to the
increase of diuretic dose from baseline. Due to skewed distribution,
NT-proBNP was assessed using logarithmically transformed values
(base 10). Variable selection inmultivariatemodelswas based on statis-
tical signiﬁcance at univariate analysis. To avoid multicollinearity, re-
dundant variables were dropped from the multivariate regression
models in the case of pairwise correlations between continuous vari-
ables [16].
The odds ratios and 95% conﬁdence intervals were also computed to
estimate the association between RRI and/or CVP and the signiﬁcant
increase in loop diuretic dose.
A p value of b0.05 was considered statistically signiﬁcant. The anal-
yses were made using Statistica 6.1 (StatSoft Inc., Tulsa, Oklahoma) and
R software (R Development Core Team, R Foundation for Statistical
Computing, Vienna, Austria).
3. Results
Two hundred and ﬁfty patients out of a total of 262 were enrolled in
the study [8]. Twelve patients were excluded for the following reasons:
two had a Doppler pattern of renal arterial stenosis, three had a poor
quality pulsed Doppler that did not permit a reliable RRI evaluation
and the remaining seven patients because of either acute decompensat-
ed heart failure or early loss to follow-up. Of the remaining 250 patients,
30 were not taking loop diuretic at baseline, and ﬁve were taking thia-
zides. Of the remaining 215 patients, 28were excluded at one year eval-
uation (14 died, 2 underwent urgent heart transplantation, 12 did not
perform 1 year evaluation). Therefore the 187 patients who made up
our study cohort underwent a 1 year evaluation. Their baseline clinical
characteristics are shown in Table 1.
Table 1
Patient baseline clinical characteristics.
Clinical characteristics of the study population
Number 187
Age (years) 65 ± 13
Males (%) 78
Ischemic cardiomyopathy (%) 40
Diabetes mellitus (%) 25
Arterial hypertension (%) 61
NYHA class 2.3 ± 0.6
Body mass index (kg/m2) 28 ± 5
Systolic arterial pressure (mm Hg) 119 ± 15
Diastolic arterial pressure (mm Hg) 69 ± 9
Heart rate (b/min) 70 ± 11
Atrial ﬁbrillation (%) 21
GFR-EPI (ml/min/1.73 m2) 69 ± 24
NT-proBNP (pg/ml) 1277 ± 1473
LVEF (%) 34 ± 9
MR (a.u.) 1.6 ± 1.1
TR (a.u.) 1.5 ± 0.9
TAPSE (mm) 19 ± 4
PASP (mm Hg) 35 ± 10
CVP N5 mm Hg (%) 16
Concomitant therapy (%)
ACE-inhibitors and/or ARBs 90
Beta-blockers 97
Loop diuretics 100
Aldosterone antagonists 66
CVP: central venous pressure. GFR-EPI: glomerular ﬁltration rate by CKD-EPI formula;
LVEF: left ventricular ejection fraction; MR: mitral regurgitation; NT-proBNP: N-terminal
pro-brain natriuretic peptide; PASP: systolic peak of pulmonary arterial pressure;
TAPSE: peak of tricuspid annular plane systolic excursion; TR: tricuspid regurgitation.
121M. Iacoviello et al. / IJC Heart & Vasculature 7 (2015) 119–1233.1. Determinants of high diuretic dose at baseline
One hundred and ﬁfty three of the patients enrolled were on low di-
uretic dose (LDD) and 34 were on high diuretic dose (HDD) therapy.
Table 2 shows the univariate predictors of baseline diuretic dose. HDD
was associated with diabetes, higher NYHA functional class, lower
LVEF and TAPSE, greater right ventricular systolic pressures, more
severe MR and TR, greater values of NT-proBNP serum levels and RRI.
At multivariate logistic regression analysis RRI remained signiﬁcant-
ly associated to baseline HDD in the different multivariate regression
models, including other univariate predictors, as shown in Table 3. In
these models CVP, PASP and TR were included separately because
they were too closely correlated to each other.Table 2
Baseline clinical and therapeutic characteristics of patients at enrolment according to low or h
dose at univariate regression analysis is reported.
Baseline LDD Base
Number 153 34
Age (years) 65 ± 13 67 ±
Ischemic cardiomyopathy (%) 37 53
Diabetes mellitus (%) 21 41
Arterial Hypertension (%) 61 65
NYHA class 2.2 ± 0.5 2.36
Body mass index (kg/m2) 28 ± 4 28 ±
Systolic arterial pressure (mm Hg) 120 ± 15 115
GFR-EPI (ml/min/1.73 m2) 71 ± 24 63 ±
NT-proBNP (pg/ml)a 1035 ± 1219 235
LVEF (%) 35 ± 9 29 ±
MR (a.u.) 1.5 ± 0.9 2.2
TR (a.u.) 1.3 ± 0.9 1.9
TAPSE (mm) 19 ± 4 17 ±
PASP (mm Hg) 35 ± 10 43 ±
CVP N5 mm Hg (%) 11 38
RRI 69 ± 9 76 ±
LDD: low diuretic dose. HDD: high diuretic dose. For the remaining abbreviations see table 1.
a After log-transformation.3.2. RRI and 1 year increase of loop diuretic dose
Of the patients enrolled, 35 (19%) reached the end-point of the sta-
ble increase in loop diuretic dose. In 12 patients the increase was conse-
quent to hospitalization due to acute decompensated heart failure and
in 23 toNYHAclassworsening. Patientswith increased oneyear diuretic
dose, when compared to those without increased dose, did not show a
signiﬁcant difference of baseline daily furosemide equivalent diuretic
dose (67 ± 67 vs. 90 ± 90mg/die, p: 0.9). At univariate Cox regression
analysis a one year increase in loop diuretic dose≥50%was signiﬁcantly
associated with age (OR: 1.26; 95% CI: 1.09–1.45; p: 0.002), GFR-EPI
(OR: 0.85; 95% CI: 0.74–0.98; p: 0.023), logarithm NT-proBNP (OR:
1.32; 95% CI: 1.14–1.51; p b 0.001), LVEF (OR: 0.86; 95% CI: 0.75–0.99;
p: 0.044), CVP (OR: 1.28; 95% CI: 1.12–1.48; p b 0.001) and RRI (OR:
1.37; 95% CI: 1.19–1.57; p b 0.001). At multivariate regression analysis
only CVP (OR: 1.214; 95% CI: 1.05–1.4; p: 0.008) and RRI (OR: 1.21;
95% CI: 1.01–1.44; p: 0.040) remained associated to the end-point.
At ROC curve (AUC: 0.71; 95% CI: 0.61–0.80) a RRI cut-off of 71
showed the best value in predicting an increase in loop diuretic dose
with a sensitivity of 79% and a speciﬁcity of 58%. Fig. 1 shows the com-
parison between groups of patients with a RRI ≥ 71 and b71 who
underwent both baseline and 1 year evaluation. Patients with higher
RRI were characterised by signiﬁcantly higher baseline loop diuretic
dosage. Moreover, diuretic dosage further and signiﬁcantly increased
after 1 year (panel A). Similarly, a greater percentage of patients with
HDD was observed in the group with higher RRI which further and sig-
niﬁcantly increased at 1 year (panel B).
Finally, in 79 patientswith RRI≥ 71 or CVP N5mmHga higher prob-
ability of an increase in loop diuretic dose ≥50% was observed com-
pared to patients without this risk factor (OR: 1.31; 95% CI: 1.13–1.52;
p b 0.001). This risk was even greater in 21 patients with both these
risk factors at baseline (OR: 1.64; 95% CI: 1.39–1.94; p b 0.001).
4. Discussion
The main ﬁnding of this study is the independent association be-
tween RRI, basal high diuretic dose and one-year increase of furosemide
dose in a population of CHF outpatients.
RRI is a parameter reﬂecting abnormalities in renal perfusion, which
we have recently found to be independently associated with heart fail-
ure progression [8]. Interestingly, even though it was strictly correlated
to the world-wide accepted marker of renal dysfunction, its predictive
value was incremental to that of estimated GFR, thus suggesting itsigh loop diuretic dose. The association among studied variables and baseline high diuretic
line HDD Univariate regression analysis
OR (95% CI)
p
12 1.04 (0.90–1.21) 0.556
1.13 (0.98–1.31) 0.092
1.19 (1.04–1.38) 0.013
1.03 (0.89–1.19) 0.673
± 0.5 1.32 (1.15–1.51) b0.001
5 0.99 (0.86–1.14) 0.880
± 14 0.87 (0.75–1.0) 0.052
23 0.87 (0.76–1.01) 0.066
6 ± 1974 1.42 (1.24–1.62) b0.001
10 0.77 (0.67–0.88) b0.001
± 1.4 1.3 (1.13–1.49) b0.001
± 1.1 1.29 (1.12–1.48) b0.001
5 0.77 (0.67–0.89) b0.001
12 1.44 (1.25–1.66) b0.001
1.34 (1.17–1.54) b0.001
6 1.39 (1.22–1.60) b0.001
Table 3
Multivariate regression models to estimate the predictors of baseline high diuretic dose.
Multivariate regression analysis
Model 1 Model 2 Model 3
OR (95% CI) P OR (95% CI) p OR (95% CI) p
Diabetes 1.11 (0.98–1.27) 0.116 1.11 (0.98–1.27) 0.111 1.11 (0.98–1.27) 0.113
NYHA 1.14 (0.99–1.31) 0.055 1.13 (0.99–1.29) 0.077 1.13 (0.99–1.30) 0.073
GFR-EPI 1.08 (0.93–1.27) 0.311 1.07 (0.91–1.26) 0.394 1.08 (0.93–1.27) 0.319
NT-proBNPa 1.12 (0.97–1.30) 0.139 1.09 (0.94–1.28) 0.240 1.15 (0.991–1.33) 0.067
LVEF 0.84 (0.73–0.96) 0.013 0.85 (0.74–0.97) 0.019 0.83 (0.72–0.96) 0.011
TAPSE 0.87 (0.77–0.99) 0.045 0.86 (0.76–0.98) 0.026 0.87 (0.76–0.99) 0.042
PVC N5 1.20 (1.05–1.38) 0.007 – – – –
RRI 1.22 (1.04–1.44) 0.018 1.206 (1.021–1.425) 0.029 1.21 (1.02–1.42) 0.030
PASP – – 1.217 (1.059–1.398) 0.006 – –
TR – – – – 1.16 (1.01–1.33) 0.041
a After log-transformation. For abbreviations see Table 1.
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incremental information carried by RRI is strictly related to the patho-
physiological conditions underlying the increase in renal vascular resis-
tance. Firstly, a high RRI may reﬂect the abnormalities of the renal
arteries related to vascular lesions [17] and/or an increased arterial stiff-
ness [6]. Secondly, intra-renal hemodynamic changes due to both pa-
renchymal and vascular abnormalities can cause an RRI increase [7].
Thirdly, a high RRI could be caused by increased CVP, as the latter deter-
mines higher intra-abdominal and intra-renal pressures [18,19]. Finally,
neurohormonal hyperactivity canworsen systemic congestion and con-
tribute to increased intravascular resistance [20].
All the abovementioned pathophysiological factors can explain the
independent relationship we found with high diuretic dose.
A decreased response of the nephron to diuretic therapy in CHF pa-
tients when compared to normal patients has been widely demonstrat-
ed. The dose–response curve shows a downward and right shift, thus
requiring a higher dose in order to achieve the same level of sodium ex-
cretion [21]. However, in CHF patients, there is a high interindividual
variability in loop diuretic response. Consequently, there could be pa-
tients with a similar left ventricular dysfunction who require either
very high or low doses in order to maintain a euvolemic state [22]. Nev-
ertheless, it is not unlikely that changes in renal perfusion can play a key
role in determining differences in the dose–response curve of diuretics.
In fact, the increased renal arterial resistance can cause water and sodi-
um retention because of the reduction in glomerular ﬁltration pressure
[23]. Moreover, the reduced GFR could lead to a reduced delivery of di-
uretic molecules to their site of action at Henle's loop [24,25].Fig. 1. Results of patients at both baseline and 1 year evaluation, according to an RRI≥71 (92 pa
in the two groups and panel B shows the percentage of patients taking high diuretic dose. * vsThe decreased diuretic response could be further worsenedwhen an
increased arterial renal resistance is associated to a high CVP [19,25]. In
this condition, a further decline in GFR could be determined by an
increase in both renal interstitial pressure and renal tubular pres-
sure [19]. As a consequence, the net hydrostatic pressure difference
between the glomerular capillaries and the tubule (i.e. one of the main
driving forces for GFR) is reduced and diuretic response can be affected
[25].
Our ﬁndings further support the potential harmful effects of RRI and
CVP by demonstrating that these parameters are also independently as-
sociated with diuretic dose increase during a mid-term follow-up. In
fact, the presence of RRI or CVP is associatedwith a higher risk of diuret-
ic dose increase and this risk becomes even greater when both factors
are present. These results suggest that the coexistence of renal venous
congestion and high arterial renal resistance can cause a progressive
loss of response to diuretics and this self-perpetuating vicious circle
could lead to diuretic resistance. However, it should also be considered
that several other mechanisms might be involved in the diuretic dose
increase at mid-term follow-up, such as neurohormonal activation,
cytochines, adaptative changes of nephrons, and the bioavailability of
oral furosemide inﬂuenced by delayed intestinal absorption.
Finally, in our study cohort no independent association was found
between GFR estimated by EPI formula and diuretic dose. Chronic kid-
ney failure can cause a change in the dose–response curve of diuretics.
In particular, the curve shifts to the right and higher doses are required
to obtain a signiﬁcant diuretic effect [26]. Nevertheless, our results sug-
gest that, themain determinant of the variability in diuretics response istients) or less?? (95 patients). Panel A shows the baseline and one yearmean diuretic dose
. RRI b 71; † vs. baseline. RRI: renal resistance index. HDD: high diuretic dose.
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related to renal blood ﬂow as opposed to GFR.
4.1. Limitations of the study
Our study is a secondary analysis of a previously published paper.
The analysis of diuretic dose was possible due to the fact that its use in
our heart failure unit is standardised and conforms to current guidelines
[1]. We did not measure RRI after one year follow-up. These data could
be interesting in order to evaluate how this parameter changes over
time and how it is related to the therapy.
In conclusion, RRI is a parameter reﬂecting arterial renal perfusion
which is independently associated with the high dose of loop diuretics
as well as with its increase during a mid-term follow-up. High central
venous pressure is also a condition independently related to the diuretic
dose increase. These data suggest the potential usefulness of renal resis-
tance index and central venous pressure assessment in order to detect
patients with an altered diuretic dose–response curve which can also
lead to the development of diuretic resistance. In addition, the present
ﬁndings may represent the basis for further investigations aimed at
optimizing therapies intended to improve renal perfusion and, as a
consequence, the response of CHF patients to diuretic therapy.
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